Answers are grounded in this paper and cite their sources.
Bempegaldesleukin (BEMPEG) is a pegylated interleukin (IL)-2 cytokine prodrug engineered to provide controlled and sustained activation of the clinically validated IL-2 pathway, with the goal of preferentially activating and expanding effector CD8
No takes yet. Share an insight, caveat, or question.
Tannir et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: